Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Efficacy and Safety of Βeta-adrenoceptor Inverse Agonist and Biased Ligand, Nadolol, In Smoking Cessation of Patients With Chronic Cough With or Without Airflow Obstruction

NCT01825122 is registered in ClinicalTrials.gov with Invion, Inc. as lead sponsor.

NCT NCT01825122
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT01825122 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Efficacy and Safety of Βeta-adrenoceptor Inverse Agonist and Biased Ligand, Nadolol, In Smoking Cessation of Patients With Chronic Cough With or Without Airflow Obstruction
Lead sponsor
Invion, Inc.
Phase
Phase 2
Overall status
Completed
Start date
March 31, 2014
Completion date
August 31, 2015
Enrollment
155 (actual)
Sites
4

Conditions

As the registry lists them; a condition with its own page is linked.

smoking cessation